Has Brendon Stiles, MD received payments from drug or device companies?

Yes. Drug and device makers reported $313,762 in general payments to Brendon Stiles, MD across 230 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brendon Stiles, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brendon Stiles, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brendon Stiles, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · New York, NYNPI 1013176387

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $272,373 of the $313,762 with a category attached, or 86.8%. 18 manufacturers reported payments, led by AstraZeneca at 49.5% of the total. Among thoracic surgery (cardiothoracic vascular surgery) clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$313,762in general payments, 2019–2025

Across 230 payments — averaging $1364.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$155K
Astrazeneca UK Limited$53K
E.r. Squibb & Sons, L.L.C.$33K
Merck$29K
Genentech USA, Inc.$13K
Pfizer$11K
plus $19K from 12 others

$177,702in research payments, 2019–2025

Across 6 payments — averaging $29,617 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Astrazeneca UK Limited$89K
AstraZeneca$72K
E.r. Squibb & Sons, L.L.C.$15K
Medtronic$2K

What the payments were for

Consulting fees$272,37387%
Speaking & faculty fees$17,3596%
Travel & lodging$15,6385%
Food & beverage$8,3933%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	125	$155,364
Astrazeneca UK Limited	31	$52,649
E.r. Squibb & Sons, L.L.C.	14	$33,446
Merck	14	$28,959
Genentech USA, Inc.	7	$13,101
Pfizer	9	$11,110
Covidien LP	6	$8,736
Regeneron	2	$2,480
Medela LLC	1	$2,000
Medtronic	4	$1,878
Regeneron Healthcare Solutions, Inc.	2	$1,828
Intuitive Surgical	8	$1,501
Atricure, Inc.	1	$184
BD	1	$148
Johnson & Johnson(2 entities)	2	$128
Ambu Inc.	1	$125
Philips North America LLC	1	$68
Smith+Nephew	1	$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TAGRISSO$91,678
IMFINZI$44,708
OPDIVO$11,785
KEYTRUDA$11,086
superDimension$8,541
LIBTAYO$4,268
TECENTRIQ$3,363
LORBRENA$3,000
XALKORI$2,205
Art. 101030215 Thopaz+ Chest Drainage$2,000
Da Vinci Surgical System$1,372
ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$184
Progel Applicator Spray Tips$148
ONGLYZA$131
Endo GIA$123
ILLUMISITE$111
Monarch Platform$106
Alecensa$103

How this compares

$313,762 in reported general payments places this provider in the 95th percentile of 383 thoracic surgery (cardiothoracic vascular surgery) providers in New York.

See all thoracic surgery (cardiothoracic vascular surgery) providers in New York →

Medicare billing

Part B allowed, 2024

$53,364

Medicare patients

Services billed

166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other thoracic surgery (cardiothoracic vascular surgery) in New York

Aubrey GallowayNew York$5.7M
Gilbert TangNew York$842K
Michael ZervosNew York$811K
Elias ZiasNew York$465K
Isaac GeorgeNew York$395K
Eugene GrossiNew York$350K
Costas BizekisNew York$321K
Daniela MolenaNew York$221K
Arnar GeirssonNew York$218K
Andrea WolfNew York$157K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →